Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Antiviral Drugs - Southern Asia

Southern Asia
  • The revenue of the Antiviral Drugs market in Southern Asia is expected to reach US$518.71m in 2025.
  • Furthermore, it is projected that the market will exhibit an annual growth rate of 2.31% between 2025 and 2029, leading to a market volume of US$568.33m by 2029.
  • In terms of global comparison, United States is anticipated to generate the highest revenue, amounting to US$31.15bn in 2025.
  • The demand for antiviral drugs in Southern Asia has surged due to the high prevalence of viral diseases in the region.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

In-Scope
  • HIV
  • Hepatitis B and hepatitis C
  • Ebola
  • COVID-19
Out-Of-Scope
  • Vaccines
  • Antibiotics
  • Immunosuppressants
  • In vitro diagnostics and rapid tests
Antiviral Drugs: market data & analysis - Cover

Market Insights report

Antiviral Drugs: market data & analysis
Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update:

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update:

    Analyst Opinion

    The Antiviral Drugs market in Southern Asia has been steadily developing in recent years, driven by a combination of customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors.

    Customer preferences:
    Customers in Southern Asia have shown a growing demand for antiviral drugs due to the increasing prevalence of viral diseases in the region. With a large population and high population density, the spread of viral diseases is a major concern in Southern Asia. Additionally, customers in the region tend to prefer affordable and easily accessible healthcare options, which has led to the growth of generic antiviral drugs in the market.

    Trends in the market:
    One of the major trends in the Antiviral Drugs market in Southern Asia is the increasing focus on research and development of new drugs to combat emerging viral diseases. With the outbreak of diseases such as COVID-19, there has been a renewed emphasis on developing effective antiviral drugs. Another trend in the market is the growing popularity of combination therapy, which involves using multiple antiviral drugs to increase effectiveness and reduce the risk of drug resistance.

    Local special circumstances:
    Southern Asia has a unique set of circumstances that have contributed to the growth of the Antiviral Drugs market. For example, the region has a high burden of viral diseases such as dengue fever, hepatitis B and C, and HIV/AIDS. Additionally, the region has a large population of low-income individuals who may not have access to expensive branded drugs, which has led to the growth of generic antiviral drugs in the market.

    Underlying macroeconomic factors:
    The Antiviral Drugs market in Southern Asia is also influenced by underlying macroeconomic factors such as government policies and healthcare infrastructure. Many governments in the region have implemented policies to promote the use of generic drugs, which has led to the growth of the generic antiviral drugs market. Additionally, the region has seen significant improvements in healthcare infrastructure in recent years, which has made antiviral drugs more accessible to the population.In conclusion, the Antiviral Drugs market in Southern Asia is developing due to a combination of customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors. The increasing prevalence of viral diseases in the region, the focus on research and development of new drugs, and the growing popularity of combination therapy are all contributing to the growth of the market. Additionally, government policies and improvements in healthcare infrastructure are making antiviral drugs more accessible to the population.

    Key Players

    Most recent update:

    Source: Statista Market Insights

    Global Comparison

    Most recent update:

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Antiviral Drugs: market data & analysis - BackgroundAntiviral Drugs: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update:

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Global pharmaceutical industry - statistics & facts

    The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.
    Meredith Alda
    Sales Manager

    Mon - Fri, 9am - 6pm (EST)

    Lodovica Biagi
    Director of Operations

    Mon - Fri, 9:30am - 5pm (GMT)

    Ayana Mizuno
    Junior Business Development Manager

    Mon - Fri, 10:00am - 6:00pm (JST)

    Carolina Dulin
    Group Director - LATAM

    Mon - Fri, 9am - 6pm (EST)

    Yolanda Mega
    Operations Manager

    Mon - Fri, 9am - 5pm (SGT)